Spots Global Cancer Trial Database for amd3100
Every month we try and update this database with for amd3100 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | NCT00396968 | Acute Myelogeno... Myelodysplastic... | AMD3100 Allogeneic Stem... | 18 Years - 60 Years | Sanofi | |
| Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | NCT00903968 | Multiple Myelom... | Plerixafor bortezomib Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) | NCT00444912 | Non-Hodgkin Lym... Hodgkin Disease | G-CSF plus pler... G-CSF plus pler... rituximab | 18 Years - 70 Years | Sanofi | |
| AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma | NCT04058145 | Head and Neck C... | AMD3100 Pembrolizumab | 18 Years - | Massachusetts General Hospital | |
| Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies | NCT00914849 | Hematologic Neo... | AMD3100 Leukopheresis Stem cell trans... | 18 Years - 65 Years | Washington University School of Medicine | |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00694590 | Chronic Lymphoc... Small Lymphocyt... | plerixafor | 18 Years - 80 Years | Sanofi | |
| AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | NCT00395967 | Multiple Myelom... Lymphoma, Non-H... | G-CSF plus pler... | 18 Years - 75 Years | Sanofi | |
| Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies | NCT00914849 | Hematologic Neo... | AMD3100 Leukopheresis Stem cell trans... | 18 Years - 65 Years | Washington University School of Medicine | |
| AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia | NCT01655875 | Pediatric Acute... Pediatric Acute... | AMD3100 | 2 Years - 22 Years | Emory University | |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00694590 | Chronic Lymphoc... Small Lymphocyt... | plerixafor | 18 Years - 80 Years | Sanofi | |
| AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia | NCT00512252 | Leukemia, Myelo... | AMD3100 Mitoxantrone Etoposide Cytarabine | 18 Years - 70 Years | Washington University School of Medicine | |
| Long-Term Follow Up Study for AMD3100 Patients | NCT00476294 | Myeloma | Telephone Quest... | 18 Years - 78 Years | M.D. Anderson Cancer Center | |
| Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma | NCT00733824 | Lymphoma, Non-H... Hodgkin Disease | AMD3100 G-CSF Apheresis | 18 Years - 75 Years | Washington University School of Medicine | |
| AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF | NCT00396266 | Multiple Myelom... Lymphoma, Non-H... | G-CSF Plus Pler... | 18 Years - 70 Years | Sanofi |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
